Intravitreal nintedanib attenuates proliferative vitreoretinopathy in a mouse model: Efficacy, safety, and mechanistic insights
- 9 June 2026
- journal article
- Published by Elsevier in Experimental Eye Research
- Vol. 270, 111115
Abstract
No abstract availableKeywords
Funding Information
- Marmara Üniversitesi (10818)
- Türkiye Sağlık Enstitüleri Başkanlığı (28352)
This publication has 44 references indexed in Scilit:
- Nintedanib inhibits neovascularization and subretinal fibrosis in a laser-induced choroidal neovascularization mouse modelBiochemical and Biophysical Research Communications, 2025
- Emerging Co‐Assembled and Sustained Released Natural Medicinal Nanoparticles for Multitarget Therapy of Choroidal NeovascularizationAdvanced Materials, 2024
- Nintedanib inhibits normal human vitreous-induced epithelial-mesenchymal transition in human retinal pigment epithelial cellsBiomedicine & Pharmacotherapy, 2023
- Nintedanib prevents TGF-β2-induced epithelial-mesenchymal transition in retinal pigment epithelial cellsBiomedicine & Pharmacotherapy, 2023
- Effect of aflibercept on proliferative vitreoretinopathy: Proteomic analysis in an experimental animal modelExperimental Eye Research, 2021
- Clinical Pharmacokinetics and Pharmacodynamics of NintedanibClinical Pharmacokinetics, 2019
- Role of epithelial–mesenchymal transition in proliferative vitreoretinopathyExperimental Eye Research, 2016
- The retinal pigment epithelium: An important player of retinal disorders and regenerationExperimental Eye Research, 2014
- A Novel Strategy to Develop Therapeutic Approaches to Prevent Proliferative VitreoretinopathyThe American Journal of Pathology, 2011
- A Mouse Model of Proliferative Vitreoretinopathy Induced by DispaseExperimental Eye Research, 2002